Medical Communications
University of Leipzig and SiSaf partner over Bio-Courier targeted miRNA
March 27, 2023 Medical Communications
SiSaf, an RNA delivery and therapeutics company, has announced a collaboration with the University of Leipzig to develop Bio-Courier targeted …
NICE recommends PTC Therapeutics’ gene therapy for NHS use
March 24, 2023 Medical Communications
NICE has recommended PTC Therapeutics’ gene therapy to the NHS for the treatment of ultra-rare disease aromatic L-amino acid decarboxylase …
Creative Medical Technology files FDA ODD application for Brittle Type 1 diabetes
March 24, 2023 Medical Communications
US-based biotech company Creative Medical Technology has announced that it has filed for the FDA’s Orphan Drug Designation (ODD) for …
European Commission delays release of major changes to pharma legislation
March 24, 2023 Medical Communications
The European Commission (EC) has again delayed the release of its new proposal for changes to Europe’s pharma legislation. The …
NeuroRPM announces FDA clearance for AI monitoring app for Parkinson’s disease on Apple Watch
March 24, 2023 Medical Communications
NeuroRPM has announced that it has received clearance from the FDA for its NeuroRPM device which uses AI and existing …
Incyte has announced FDA approval of Zynyz
March 23, 2023 Medical Communications
Incyte has today announced that the FDA gas approved Zynyz (retifanlimab-dlwr) for the treatment of adult patients with metastatic or …
India cancels manufacturing licence for Marion Biotech after cough syrup deaths
March 23, 2023 Medical Communications
Uttar Pradesh, a state in India, has cancelled the manufacturing licence of Marion Biotech after two cough syrups made at …
Roche and Eli Lilly collaborate on Alzheimer’s disease blood test
March 22, 2023 Medical Communications
Swiss biotech company Roche has announced a collaboration with US pharmaceutical company Eli Lilly to develop Roche’s Elecsys Amyloid Plasma …
FDA staff appear to support Biogen’s ALS drug despite limited data
March 21, 2023 Medical Communications
It appears that the FDA is inclined to support Biogen’s amyotrophic lateral sclerosis (ALS) drug, tofersen, with documents released on …
FDA approves Surgvision’s Explorer Air II device
March 21, 2023 Medical Communications
Medical technology company Surgvision has announced that it has received FDA 510(k) approval for its Explorer Air II device. It …
AstraZeneca and MSD announce MHRA marketing authorisation of Lynparza combination therapy
March 20, 2023 Medical Communications
AstraZeneca and MSD have announced that the MHRA has granted marketing authorisation for Lynparza (olaparib) in the UK, when used …
Oxford Nanopore and 4bases collaborate on kit for BRCA1 and BRCA2 gene analysis
March 20, 2023 Medical Communications
Oxford Nanopore Technologies and Swiss company 4bases have announced a collaboration making 4bases kits with Oxford Nanopore’s sequencing technology. These …
FDA approves Novartis’ Tafinlar and Mekinist combination
March 17, 2023 Medical Communications
The FDA has approved Novartis’ combination therapy, Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of BRAF V600E low-grade glioma …
CANbridge Pharmaceuticals reports positive long-term data for glioblastoma multiforme drug
March 17, 2023 Medical Communications
Chinese biopharmaceutical company CANbridge Pharmaceuticals has announced positive long-term follow-up data from its clinical studies into a glioblastoma multiforme (GBM) …
Great Ormand Street Hospital enters commercial agreement with Leucid Bio
March 16, 2023 Medical Communications
Leucid Bio and Great Ormand Street Hospital NHS Foundation Trust (GOSH) have entered a commercial agreement to manufacture Leucid’s lead …
Latest content
October 26, 2026
